Search results
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
Motley Fool via Yahoo Finance· 1 day agoPfizer's slightly higher dividend yield and broad pipeline give it the edge in this comparison. That...
Pfizer stock price analysis: how PFE became a fallen angel | Invezz
Invezz· 1 day agoPfizer (NYSE: PFE) stock price has crashed hard in the past few years as demand for Covid-19...
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Zacks via Yahoo Finance· 20 hours agoInvestors should also take note of any recent adjustments to analyst estimates for Pfizer. Such...
Park National Corp OH Lowers Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 7 hours agoThe institutional investor owned 446,577 shares of the biopharmaceutical company’s stock after selling 23,764 shares during the quarter. Park National Corp OH’s holdings in ...
Pfizer (NYSE:PFE) Stock Price Down 0.9%
ETF DAILY NEWS· 4 days agoPfizer Inc. (NYSE:PFE – Get Free Report) was down 0.9% during trading on Thursday . The company traded as low as $27.20 and last traded at $27.41. Approximately 11,513,196 ...
Cantor Fitzgerald Reiterates “Overweight” Rating for Pfizer (NYSE:PFE)
ETF DAILY NEWS· 15 hours agoCantor Fitzgerald’s price target indicates a potential upside of 64.17% from the stock’s previous close. Morgan Stanley upped their target price ...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 6 days agoBenefits For Regenxbio, Solid But most analysts didn't consider Pfizer a serious competitor. "The...
Pfizer Inc. (NYSE:PFE) Shares Sold by CoreFirst Bank & Trust
ETF DAILY NEWS· 1 day agoThe fund owned 42,156 shares of the biopharmaceutical company’s stock after selling 1,011 shares during the period. CoreFirst Bank & Trust’s holdings in Pfizer< ...
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
Zacks via Yahoo Finance· 7 days agoPfizer (PFE) closed the latest trading day at $27.66, indicating a -1.32% change from the previous...
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Morningstar· 6 days agoShares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said ...